



eFFECTOR Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

September 6, 2022

SAN DIEGO and REDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at the upcoming **H.C. Wainwright 24th Annual Global Investment Conference**.

Presentation Date: Monday, September 12, 2022
Time: 9:30 AM ET
Presenter: Steve Worland, Ph.D., President and Chief Executive Officer
Presentation Link: <https://journey.ct.events/view/f2daafb6-6fa4-4087-9078-8140c7335ffa>
Conference Website: <https://hcwevents.com/globalconference/>

A live webcast will be available on the "Events and Presentation" page of the Investors section of the Company's website at www.effector.com. A replay of the webcast will be available for 30 days following the event. For more information, please visit <https://investors.effector.com/>.

About eFFECTOR Therapeutics

eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR's STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR's product candidates is designed to act on a single protein that drives the expression of a network of functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR's lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR's inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. In addition to the company's oncology focus, zotatifin is being evaluated as a potential host-directed anti-viral therapy in patients with mild to moderate COVID-19 in collaboration with the University of California, San Francisco, under a \$5 million grant sponsored by the Defense Advanced Research Projects Agency.

Contacts:

Investors:

Christopher M. Calabrese
Managing Director
LifeSci Advisors
917-680-5608
ccalabrese@lifesciadvisors.com

Kevin Gardner
Managing Director
LifeSci Advisors
617-283-2856
kgardner@lifesciadvisors.com

Media:

Heidi Chokeir, Ph.D.
Managing Director
Evoke Canale
619-203-5391
Heidi.chokeir@evokegroup.com